Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Gastroenterology. 2017 Feb 4;152(6):1310–1318.e1. doi: 10.1053/j.gastro.2017.01.042

Figure 2.

Figure 2

Proportion of patients without rebleeding (Rebleed free) during 30 days after randomization. Top curve is Doppler patients and lower curve is standard treated patients. Product limit plots, compared by Log-rank test. p = 0.0174.

** These included esophageal varices or portal hypertensive lesions (87 patients) and no SRH or UGI lesions that did not meet endoscopic inclusion criteria (288 patients).